Menu
Not yet recruiting NCT07213596

Virtual Reality Treatment for Trauma Related to COVID-19 Infection

No phase Interventional PTSD PTSD Symptoms

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: VR Exposure Therapy, Cognitive Behavioral Therapy (CBT), Supportive Psychotherapy.
Who it may be relevant to
Registry conditions: PTSD, PTSD Symptoms. Basic parameters: 18 years — 64 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Development of Virtual Reality Treatment Technology to Treat Trauma Related to COVID-19 Infection

Overview

This clinical trial aims to develop and evaluate the effectiveness of virtual reality (VR)-based exposure therapy for trauma symptoms related to COVID-19 infection. The intervention targets healthcare workers and individuals from the general population who experienced pandemic-related psychological distress. The study assesses psychological and physiological outcomes, including PTSD, anxiety, depression, HRV, and EEG biomarkers.

Detailed description

The project involves a two-phase clinical study. In Phase 1, VR exposure therapy content is developed based on trauma management theory and tailored to specific participant groups (e.g., COVID-19 survivors, healthcare workers). In Phase 2, randomized controlled trials will compare VR treatment with standard therapy approaches (CBT, supportive therapy) across two populations:

Healthcare workers involved in the care of COVID-19 patients Members of the general public affected by social disaster-related psychological distress

Participants will undergo 5 weekly sessions of VR exposure therapy. Pre- and post-intervention assessments will include standardized psychiatric scales (e.g., PHQ-9, PCL-5), HRV, and EEG measurements. The trial aims to validate the efficacy and safety of customized VR therapy protocols and identify relevant biomarkers for treatment prediction.

Interventions

  • Behavioral VR Exposure Therapy
    Virtual Reality Exposure Therapy (VRET) is a form of psychotherapy that uses immersive virtual environments to simulate trauma-related stimuli in a controlled and safe setting, allowing individuals to gradually confront and process distressing memories or triggers. VRET is grounded in prolonged exposure (PE) therapy, a well-established treatment for PTSD and anxiety disorders. In this study, VRET is delivered in 5 weekly sessions, each lasting approximately 50 minutes, using a customized VR sy
  • Behavioral Cognitive Behavioral Therapy (CBT)
    Face-to-face CBT with exposure elements, targeting trauma-related symptoms. Administered in 5 weekly sessions.
  • Behavioral Supportive Psychotherapy
    Therapist-led supportive therapy (TAU), focusing on empathy, validation, and emotional support without structured exposure.

Primary outcome measures

  • Change in PTSD symptoms [Time frame: baseline, week 5, 3-mo follow-up]

Eligibility criteria

Inclusion criteria

  • Age 18-64, healthy population who survived from COVID-19 (COVID survivors) or Healthcare Workers with PCL-5 ≥10, GAD-7/PHQ-9 ≥10

Exclusion criteria

  • Pregnancy, neurological disorders, severe medical conditions

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07213596 · SCHCA IRB 2022-08-032-033 · RS-2022-KH125605

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗